Selective Serotonin Reuptake Inhibitor Use Associated with Decreased Growth in Children

Primary Psychiatry

Volumn 10, Issue 2, 2003, Pages 23-24

  Ginsberg, David L ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CLONIDINE; FLUOXETINE; FLUVOXAMINE; GROWTH HORMONE; METHYLPHENIDATE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; ATTENTION DEFICIT DISORDER; CASE REPORT; CHILD GROWTH; CLINICAL FEATURE; FEMALE; FOLLOW UP; GILLES DE LA TOURETTE SYNDROME; GROWTH DISORDER; GROWTH RATE; HUMAN; MALE; OBSESSIVE COMPULSIVE DISORDER; REVIEW; SCHOOL CHILD; SMALL FOR DATE INFANT; TREATMENT OUTCOME;

EID: 1842557746     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (3)

1. Weintrob N, Cohen D, Klipper-Aurbach Y, et al. Decreased growth during therapy with selective serotonin reuptake inhibitors. Arch Ped Adoles Med. 2002;156:696-701.
2. O'Flynn K, O'Keane V, Lucey JV, et al. Effect of fluoxetine on noradrenergic mediated growth hormone release: a double-blind, placebo-controlled study. Biol Psychiatry. 1991;30:377-382.
3. Coplan JD, Papp LA, Martinez J, et al. Persistence of blunted human growth hormone response to clonidine in fluoxetine-treated patients with panic disorder. Am J Psychiatry. 1995;152:619-622.